Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Ltd ADR (TAK)

Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Takeda Pharmaceutical Ltd ADR 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU TOKYO M0 103-8668 JPN

www.takeda.com P: 813-3278-2111 F: +81 332782268

Description:

Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.

Key Statistics

Overview:

Market Capitalization, $K 41,649,004
Enterprise Value, $K 70,130,200
Shares Outstanding, K 3,164,818
Annual Sales, $ 29,803 M
Annual Net Income, $ 2,346 M
Last Quarter Sales, $ 7,556 M
Last Quarter Net Income, $ 718,900 K
EBIT, $ 6,831 M
EBITDA, $ 11,747 M
60-Month Beta 0.53
% of Insider Shareholders 0.04%
% of Institutional Shareholders 9.17%
Float, K 3,163,552
% Float 99.96%
Short Volume Ratio 0.48

Growth:

1-Year Return -20.58%
3-Year Return -22.86%
5-Year Return -28.48%
5-Year Revenue Growth 87.03%
5-Year Earnings Growth 93.46%
5-Year Dividend Growth -13.33%

Per-Share Information:

Most Recent Earnings 0.51 on 02/01/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm 1.95
EPS Growth vs. Prev Qtr 2.00%
EPS Growth vs. Prev Year 10.87%
Annual Dividend Rate, $ 0.26
Annual Dividend Yield 1.98%
Most Recent Dividend 0.261 on 09/28/23
Next Ex-Dividends Date 09/28/23
Dividend Payable Date 12/11/23
Dividend Payout Ratio 26.96%

TAK Ratios

Ratio
Price/Earnings ttm 6.74
Price/Earnings forward 10.58
Price/Earnings to Growth 3.74
Return-on-Equity % 12.57%
Return-on-Assets % 5.89%
Profit Margin % 7.87%
Debt/Equity 0.69
Price/Sales 1.54
Price/Cash Flow 3.69
Price/Book 0.91
Book Value/Share 14.49
Interest Coverage 3.21

TAK Dividends

Date Value
09/28/23 $0.2610
09/29/22 $0.2700
09/29/21 $0.3320
09/29/20 $0.3600
09/27/19 $0.3000
09/27/18 $0.2880
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar